Levosimendan: A New Dual‐action Drug in the Treatment of Acute Heart Failure
Why the study?
Does levosimendan improve survival and haemodynamics compared to dobutamine in patients hospitalised for acute heart failure?
Population
More than 900 patients hospitalised for cardiac decompensation due to acutely worsened chronic heart failure…
Comparison
Levosimendan given as short-term therapy vs Dobutamine
Design
Review
Follow-up
180 days
Authors
Discussion
Loading...
Member takes
Implication
Should not yet change dobutamine preference in acute HF; leaves open confirmation in prospective RCTs.
Structured PICO
Does levosimendan improve survival and haemodynamics compared to dobutamine in patients hospitalised for acute heart failure?
P
Population
More than 900 patients hospitalised for cardiac decompensation due to acutely worsened chronic heart failure or to heart failure following myocardial infarction (based on four key clinical studies).
I
Intervention
Levosimendan given as short-term therapy
C
Comparator
Dobutamine
O
Outcome
Mortality rates at 31 days and 180 days post-treatmenthard clinical
Levosimendan provides substantial haemodynamic and survival benefits over dobutamine in patients with acutely decompensated heart failure.
Cite This Study
Mebazaa et al. (2003) studied this question.